Green tea: prevention and treatment of cancer by nutraceuticals
- 1 September 2004
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 364 (9439) , 1021-1022
- https://doi.org/10.1016/s0140-6736(04)17076-1
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemiaBlood, 2004
- Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and ChemotherapyJournal of Clinical Oncology, 2004
- Fundamental Concepts of the Angiogenic ProcessCurrent Molecular Medicine, 2003
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJournal of Clinical Investigation, 2003
- Green Tea Catechins as Novel Antitumor and Antiangiogenic CompoundsCurrent Medicinal Chemistry - Anti-Cancer Agents, 2002
- Cancer chemoprevention by dietary constituents: a tale of failure and promiseThe Lancet Oncology, 2001
- Phase I Trial of Oral Green Tea Extract in Adult Patients With Solid TumorsJournal of Clinical Oncology, 2001
- Angiogenesis inhibited by drinking teaNature, 1999
- Reduced Risk of Esophageal Cancer Associated With Green Tea ConsumptionJNCI Journal of the National Cancer Institute, 1994